Founded in 2008, Esperion is focused on bringing new medicines to market that address unmet needs of patients and healthcare ...

For Esperion Therapeutics, 2024 has marked a pivotal transformation in its mission to combat cardiovascular disease. CEO Sheldon Koenig, who brings over 25 years of cardiovascular industry experience, ...

Okay. Good morning, everybody. I'm Kristen Kluska, one of the biotech analyst at Cantor. Thank you so much to the Esperion Therapeutics team for being here today. We have Sheldon Koenig, the CEO; and ...

Starting with the Clear Outcomes study in 2023, which gave Esperion Therapeutics immediate success with more than 1 billion impressions globally, the company has been creating a pipeline to keep its ...

Hello, ladies and gentlemen, and thank you for standing by, and welcome to Esperion's Second Quarter 2025 financial results. [Operator Instructions] Please be advised that today's conference is being ...

With us on today’s call are Sheldon Koenig, President and CEO; and Ben Halladay, CFO. Other members of the executive team will be available for Q&A following our prepared remarks. We issued a press ...